ARTICLE | Company News
Potomac Pharma Inc., Stanley Medical Research Institute deal
October 25, 2004 7:00 AM UTC
The institute will invest $2.2 million in Potomac in the form of a convertible bond toward the development of P-101, an adrenergic receptor alpha 2 antagonist that is in Phase II trials to treat schi...